By Suherman Candra Maholtra 
In a significant advancement for global respiratory health, a multi-disciplinary team of researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health has announced the development of an experimental therapeutic DNA vaccine for tuberculosis (TB). Unlike traditional vaccines that aim solely to prevent initial infection, this novel candidate is delivered intranasally and specifically engineered to bolster the immune system’s ability to hunt down and eliminate "persister" bacteria—drug-tolerant microbes that often survive standard antibiotic courses and lead to life-threatening relapses.
The study, recently published in the Journal of Clinical Investigation, addresses a critical bottleneck in the global fight against tuberculosis: the persistence of Mycobacterium tuberculosis within the host despite months of intensive chemotherapy. By utilizing a unique genetic fusion delivered directly to the respiratory mucosa, the vaccine appears to bridge the gap between pharmaceutical intervention and long-term immunological clearance.
The Global Burden of Tuberculosis: A Persistent Adversary
Tuberculosis is not merely a disease of the past; it remains one of the most formidable pathogens in human history. Genomic evidence suggests that Mycobacterium tuberculosis has afflicted the human species for at least 6,000 years, evolving alongside its host to become a master of evasion. Despite the advent of antibiotics in the mid-20th century, TB continues to claim more lives annually than any other single infectious agent, with the exception of the peak years of the COVID-19 pandemic.
According to the 2024 Global Tuberculosis Report by the World Health Organization (WHO), the statistics remain staggering. Approximately 2 billion people—roughly one-quarter of the world’s population—carry a latent TB infection. While these individuals do not exhibit symptoms and are not contagious, they harbor a "ticking time bomb" of bacteria that can reactivate if the immune system becomes compromised. In 2024 alone, more than 10 million people progressed to active TB, and 1.2 million succumbed to the disease.
The primary challenge in treating active TB is the duration and complexity of the regimen. Standard treatment for drug-susceptible TB requires a minimum of six months of daily medication. For multidrug-resistant TB (MDR-TB), treatment can stretch to 18 months or longer, involving drugs with significant side effects. The lengthy duration is necessitated by "persisters"—a subpopulation of bacteria that enter a semi-dormant, metabolic state where they are largely invulnerable to antibiotics that target actively dividing cells.
A New Paradigm: The Therapeutic Vaccine Approach
The World Health Organization has increasingly called for the development of therapeutic vaccines to complement existing drug therapies. The goal is to create a synergistic effect where drugs kill the bulk of the bacterial load while the vaccine "trains" the immune system to mop up the remaining persisters. This could potentially shorten treatment times from months to weeks and significantly reduce the rate of relapse.
"Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster, reduced lung inflammation and prevented relapse after treatment ended," stated Styliani Karanika, M.D., the study’s lead author and assistant professor of medicine at the Johns Hopkins University School of Medicine.
The research indicates that the vaccine does more than just assist standard treatments; it enhances the efficacy of the modern "BPaL" regimen—a combination of bedaquiline, pretomanid, and linezolid used for highly resistant strains. This suggests the vaccine could be a vital tool in treating the most difficult cases of MDR-TB and extensively drug-resistant TB (XDR-TB).
Engineering the Vaccine: The Role of relMtb and Mip3α
The experimental vaccine utilizes a sophisticated genetic design to overcome the natural "stealth" of the TB bacterium. It combines two specific genes: relMtb and Mip3α.
The first component, the relMtb gene, is derived from the TB bacterium itself. In nature, this gene produces the RelMtb protein, which acts as a survival switch. When the bacterium senses a hostile environment—such as the presence of antibiotics, low oxygen levels, or a lack of nutrients—RelMtb triggers a state of dormancy. By including this gene in the vaccine, researchers are essentially "showing" the immune system the very tool the bacteria use to hide.
The second component, Mip3α (Macrophage Inflammatory Protein-3 alpha), acts as a biological flare or homing signal. It is a potent chemoattractant for immature dendritic cells. Dendritic cells are the "sentinels" of the immune system; they are responsible for capturing foreign proteins (antigens) and presenting them to T-cells, which then coordinate a specialized attack.
By fusing these two genes, the vaccine creates a signal that draws dendritic cells directly to the site of the TB antigens. "Fusing relMtb with the Mip3α gene produces a signal that attracts immature dendritic cells—key cells that pick up TB proteins and ‘present’ them to T-cells," Karanika explained. This ensures that the immune system does not just see the bacteria, but actively prioritizes them as a target for destruction.
Intranasal Delivery: Strengthening the Front Lines
The choice of intranasal delivery is a strategic one based on the biology of infection. Tuberculosis is primarily a respiratory disease, transmitted through airborne droplets and taking root in the lungs. Traditional vaccines, usually administered via intramuscular injection, generate systemic immunity but may not produce a strong enough "local" response in the respiratory mucosa.
By delivering the DNA vaccine through the nose, the Johns Hopkins team targets the respiratory mucosa directly. This localized approach helps generate resident memory T-cells—immune cells that stay within the lung tissue for long periods, ready to react immediately upon encountering the pathogen. This creates a two-tier defense: a localized "border patrol" in the airways and a systemic "reserve force" in the bloodstream.
Experimental Evidence: From Mice to Macaques
The efficacy of the Mip3α/relMtb vaccine was tested through a series of rigorous animal models. In the initial phase involving mice, the results were highly promising. The researchers observed:
- Enhanced Recruitment: A significant increase in the activation and organization of dendritic cells and T-cells within the lung tissue.
- Dual T-Cell Activation: The vaccine successfully stimulated both CD4 (helper) and CD8 (killer) T-cells, providing a comprehensive immune response.
- Sterilization and Prevention: Mice receiving the vaccine alongside antibiotics cleared the infection faster than those receiving antibiotics alone, and notably, they showed zero relapse after the cessation of treatment.
To validate these findings in a model more similar to human biology, the team moved to rhesus macaques. The nonhuman primate study confirmed that the intranasal delivery generated measurable, TB-specific immune responses in both the blood and the airways. Crucially, these immune responses remained detectable for at least six months, indicating a level of durability necessary for a viable clinical product.
While the primate study focused on immune activation rather than "challenge" (exposure to active TB), the results serve as a vital translational bridge. The similarity between the macaque immune response and the successful mouse clearance data provides a strong foundation for future human clinical trials.
Implications for Public Health and Manufacturing
The move toward DNA-based vaccines offers several practical advantages for global health. DNA vaccines are generally more stable at varying temperatures than traditional protein-based or mRNA vaccines, which often require strict "cold chain" logistics. This stability makes them particularly suitable for deployment in low- and middle-income countries, where the TB burden is highest and infrastructure may be limited.
Furthermore, the production of DNA vaccines can be scaled efficiently. If the Mip3α/relMtb candidate continues to show success in human trials, it could be manufactured at a cost-point that allows for mass distribution.
The broader implication of this research is a shift in how we view infectious disease management. Rather than relying solely on the "slash and burn" approach of high-dose antibiotics—which can lead to toxicity and the evolution of resistant strains—the future of TB care may lie in "immunotherapy." By leveraging the body’s own defense mechanisms, clinicians may finally be able to eradicate the "persister" populations that have allowed tuberculosis to haunt humanity for six millennia.
Future Research and Funding
Despite the optimistic results, Dr. Karanika and her colleagues emphasize that more work is needed. The next steps involve further preclinical safety assessments and the design of Phase I human clinical trials to evaluate safety and immunogenicity in humans.
The research was supported by a robust network of federal and private funding, reflecting the high priority placed on TB innovation. Major contributors included several grants from the National Institutes of Health (NIH), the Gilead HIV Research Scholar Award, and the Johns Hopkins University Tuberculosis Research Advancement Center.
As the global community works toward the WHO’s goal of ending the TB epidemic by 2030, innovations like the Johns Hopkins intranasal DNA vaccine represent a necessary evolution in medical science—turning the tide against a persistent foe by targeting its very means of survival.
